Cortexyme, Inc. was a clinical-stage biopharmaceutical company founded to develop disease-modifying therapeutics for Alzheimer's disease, with a lead program (atuzaginstat / COR388) targeting the gingipain proteases of Porphyromonas gingivalis. After its lead Alzheimer's program failed in 2021, the company rebranded as Quince Therapeutics (NASDAQ: QNCX) effective August 1, 2022, pivoting to rare disease therapeutics. Quince acquired EryDel S.p.A. in October 2023 to obtain its AIDE platform and lead Phase 3 asset eDSP (encapsulated dexamethasone sodium phosphate) for ataxia-telangiectasia (A-T). Topline Phase 3 NEAT results in January 2026 missed the primary endpoint.
Cortexyme is publicly traded
IPO'd on May 9, 2019
This company is no longer available on our private secondary market. Shares can be traded publicly under CRTX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2012
Total Funding
$98.5M
2 rounds
Total raised $98.5M across 2 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series B
Date
October 16, 2018
Amount
$76M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| October 16, 2018 | Series B | $76M | — | Vulcan Capital |
| April 15, 2015 | Series A | $22.5M | — | Pfizer Venture Investments, Takeda Ventures, Sequoia Capital +4 more |
Dirk Thye
Chief Executive Officer
Brendan Hannah
Chief Business Officer & Principal Financial Officer
Charles Ryan
President
Guenter R. Janhofer
Chief Medical Officer
David Lamond
Chairperson of the Board
Competitor list is illustrative and may be incomplete, stale, or erroneous.
IntraBio
Clinical-stage biotech developing therapies for rare neurological diseases including ataxia-telangiectasia and Niemann-Pick.
PTC Therapeutics
Rare disease biopharma with neurology focus; commercial and clinical programs in pediatric rare CNS disorders.
Stoke Therapeutics
Clinical-stage rare neurogenetic disease biotech developing antisense oligonucleotide therapies.
Ultragenyx Pharmaceutical
Commercial-stage rare disease biopharma developing therapies for serious genetic disorders.
Yes, Cortexyme is publicly traded under the ticker symbol CRTX on the NASDAQ. The company went public in May 9, 2019.
Cortexyme trades under the ticker symbol CRTX on the NASDAQ. It began trading in May 9, 2019.
Cortexyme (CRTX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CRTX to place an order.
Cortexyme went public in May 9, 2019 via ipo. Cortexyme IPO'd on Nasdaq under ticker CRTX on May 9, 2019 at $17.00/share (4.412M shares). Rebranded to Quince Therapeutics on August 1, 2022, changing ticker to QNCX. Remains publicly traded on Nasdaq.
Cortexyme raised $98.5M across 2 disclosed funding rounds prior to its public listing.
Cortexyme is headquartered in South San Francisco, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.